BOSTON SCIENTIFIC CORP SEC Filings

FMR LLC and Abigail P. Johnson report beneficial ownership of Boston Scientific Corp common stock on a Schedule 13G/A. FMR LLC reports beneficial ownership of 46,378,258.61 shares, representing 3.1% of the outstanding common stock, as of June 30, 2026. FMR LLC has sole voting power over 39,968,563.03 shares and sole dispositive power over 46,378,258.61 shares, with no shared voting or dispositive power. Abigail P. Johnson reports sole dispositive power over the same 46,378,258.61 shares, but no voting power. The filing notes that one or more other persons may receive dividends or sale proceeds from these shares, but no such person holds more than five percent of the total outstanding common stock.

Boston Scientific Corp director David C. Habiger reported open-market purchases of Common Stock on two days in August 2026. He bought 1,042 shares on August 3 at a weighted average price of $48.0655 per share and 140 shares on August 4 at a weighted average price of $48.5879 per share. Each trade was executed through multiple transactions within stated price ranges, with detailed per-trade pricing available on request.

Boston Scientific CEO Michael F. Mahoney purchased 186,240 shares of common stock on August 3, 2026 at a weighted average price of $48.3323 per share, with individual trades between $47.87 and $48.47. After this open-market buy, he directly owns 1,590,024 shares and indirectly holds 22,119 shares via a 401(k) Retirement Savings Plan following a discretionary rebalancing transaction at $48.4300 per share.

Boston Scientific Corp director Edward J. Ludwig purchased 5,000 shares of common stock on July 31, 2026 at an average price of $45.4799 per share. After this open-market or private transaction, he directly owns 30,359 shares. The trade was not reported under a Rule 10b5-1 plan.

Boston Scientific Corp executive Joseph Michael Fitzgerald, EVP & Group President, Cardiology, reported a discretionary acquisition of 64,198 shares of common stock on 2026-07-31 through a rebalance of his holdings under the company’s 401(k) Retirement Savings Plan at $46.73 per share. These shares are held indirectly via the 401(k), which now reflects that balance. Separate entries show 213,907 shares held directly and 5,234 shares held by his child, with a footnote stating he disclaims beneficial ownership of the child’s shares.

Boston Scientific Corporation reported strong results for the quarter ended June 30, 2026, with net sales of $5.442 billion, up 7.5 percent on a reported basis and 7.0 percent on an operational and organic basis versus a year earlier. GAAP net income attributable to common stockholders was $907 million, or $0.61 per diluted share, compared with $797 million, or $0.53 per share. Adjusted EPS was $0.86, up from $0.75 and above the company’s guidance range of $0.82 to $0.84.

MedSurg net sales were $1.818 billion, up 5.9 percent reported, while Cardiovascular reached $3.624 billion, up 8.3 percent. Regional growth was 6.2 percent in the U.S., 11.2 percent in Asia-Pacific and 22.4 percent in Latin America and Canada on a reported basis.

The company completed a $2 billion accelerated share repurchase program, buying approximately 40 million shares, and invested $1.5 billion for an approximately 34 percent stake in MiRus LLC with an exclusive option on its TAVR business. For 2026, it projects reported net sales growth of 5.5 to 6.5 percent and adjusted EPS of $3.28 to $3.32, with third-quarter adjusted EPS expected at $0.80 to $0.82.

Boston Scientific Corporation approved a new global restructuring program, the 2026 Restructuring Plan, on July 21, 2026. The plan is intended to drive sustained cost efficiencies and support growth by optimizing the supply chain, transferring certain production lines among facilities, and reshaping functional and organizational structures.

The program is expected to be initiated in 2026 and substantially completed by the end of 2029. Boston Scientific estimates total pre-tax charges of $700 million to $800 million, including $300 million to $350 million of transfer costs, $275 million to $300 million of termination benefits, and $125 million to $150 million of other costs such as consulting, contractual cancellations, program management, accelerated depreciation and fixed asset write-offs. Of the total charges, $600 million to $700 million are expected to result in future cash outlays.

The company expects the plan to reduce gross annual pre-tax expenses by approximately $500 million as benefits are realized, with a substantial portion of these savings to be reinvested in strategic growth initiatives. While new roles will be created in growth areas, the company does expect some headcount reductions as a result of the restructuring.

Boston Scientific EVP and CFO Jonathan Monson reported routine equity compensation activity involving restricted stock units. He exercised 2,087 restricted stock units into 2,087 shares of common stock and, in a related tax-withholding disposition, 1,010 shares were withheld at a price of $43.06 per share to cover tax obligations. After these transactions, he directly holds 39,063 shares of common stock and 6,263 restricted stock units, which each represent a commitment by the company to issue one share of common stock in the future, with shares to be issued in four equal annual installments beginning on July 1, 2026.